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Dapsone: A Sticky Solution for Neutrophil Adhesion 
Dapsone provides effective therapy for skin diseases in which there 
is deposition of immunoglobulin accompanied by an accumulation 
of neutrophils; for example, bullous pemphigoid, bullous lupus ery-
thematosus, and linear IgA bullous dermatosis. Although dapsone 
disrupts several metabolic functions in neutrophils, it also inhibits 
accumulation of these cells in the skin. Neutrophils express Fc re-
ceptors for both IgG and IgA. A neutrophil adhesion assay showed 
binding of neutrophils to these antibodies accumulated in the base-
ment membrane zones of skin sections from patients with bullous 
pemphigoid and linear IgA bullous dermatosis. A modification of 
this assay was used by Zone and his co-workers (Nguyen, p. 349) to 
examine the mode of action of dapsone. They used human skin 
sections incubated with sera containing IgG or IgA antibodies from 
bullous pemphigoid or linear IgA bullous dermatosis patients as a 
substrate for neutrophil binding. Dapsone-treated neutrophils 
showed a dose-dependent inhibition of cellular binding to the im-
mobilized immunoglobulins. Further, when antiserum isolated 
from a linear IgA bullous dermatosis patient under treatment with 
dapsone was used as a source ofIgA, neutrophil binding was consist-
ently reduced. Direct treatment of purified linear IgA bullous der-
matosis IgA with dapsone also produced a similar effect. 
The authors prorose that accumulation ofIgA is a primary event 
in development 0 cutaneous lesions in these dermatoses. Subse-
quent adherence of neutrophils to IgA is necessary for cellular locali-
zation and development of the skin lesions. Others noted that dap-
~one may re~ulate the extravasation of neutrophils by disrupting 
Integr.m-med~ated a~h~r~nce. Here we see that cellular binding to 
depOSits ofIg IS also mhlblted. Although the mechanism of action of 
da!:,sone is still unknown, re~ucing the localized binding of neutro-
phlls may account for the climcal efficacy of this drug in antibody-
mediated dermatoses. 
How Irritating Is the Vehicle? 
Retinoic acid (RA) is used or is under investigation in the treatment 
of acne, photoaging, skin carcinoma, and diseases of keratinization. 
Topical application of RA produces a pleiotropic response, as does 
administration of other compounds that act through nuclear 
steroid-like receptors. Among the obvious early effects are ery-
thema and scaling of the skin. There is a limited infiltration of 
inflammatory cells despite apparent irritation. RA treatment pro-
duces an increase in proliferation of dermal keratinocytes and an 
inhibition of their terminal differentiation. At least three high-
affinity RA receptors recognize genetic transcription response ele-
ments. Each RA-receptor complex probably activates induction of 
several genes in different tissues and different developmental 
growth programs. There are also cytoplasmic RA-binding proteins, 
CRABP-I and CRABP-II. Although these molecules have a high 
affinity for RA, their function is unknown. It is important to deter-
mine events within cells that are direct markers of retinoid action. 
This will provide an assay to screen for therapeutic retinoid com-
pounds with less irritating side effects. 
Previous studies have shown that RA treatment does not influ-
ence t.he levels .of RA rec~ptors in human keratinocytes. However, 
~here IS a selective expressIOn of CRABP-II in keratinocytes, which 
IS markedly Increased by RA treatment. Mice show similar cutane-
ous respo.nses aft~r inges.tion of retinoids. This suggested that the 
resp.onse IS retinOid-specific; however, non-specific irritants in the 
vehicle could be responsible. In this issue Elder et al (p. 356), using a 
broad d~se range,. ha~e c~mpared the cutaneous response to topical 
apphcatlOn of r~t1nolc aCid, sodium dedecyl sulfate (SDS), and the 
apphcatlon ve~lcle alone. They evaluated erythema, the histology 
~f punch bIOpSies, and the level of mRNA for CRABP-II, cyclophi-
lin, and the P-RA receptor in treated and untreated skin. In addition, 
they assayed mRNA levels after incubation of secondary cultures of 
dermal fibroblasts with these agents. They have clearly shown that 
erythema and histologic changes could be produced equally by 2% 
SDS and 0.1 % RA. However, a lOOO-times lower dose of RA than 
SDS elicited a potent increase in CRABP-II mRNA level. The 
effect was specific for this message because cyclophilin and RA 
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